RxDoctor Payments Data

Bingzhong Chen, MD

Neurology · Washington, MONPI 1306058292

Payments from drug & device makers

$12,410in general payments, 2019–2025

Across 691 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Greenwich Biosciences, Inc.$1K
  • Abbott$961
  • Novartis$896
  • UCB, Inc.$649
  • Biogen$589
  • plus $7K from 46 others

What the payments were for

  • Speaking & faculty fees$390%
  • Travel & lodging$6385%
  • Food & beverage$11,73395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,410 in reported general payments places this provider in the 70th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$206,963
Medicare patients
332
Services billed
13,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab14$119,292
Aimovig AutoinjectorErenumab-Aooe20$26,497
Emgality PenGalcanezumab-Gnlm29$23,438
UbrelvyUbrogepant13$21,981
BriviactBrivaracetam12$16,561
Memantine Hcl431$9,891
Ajovy AutoinjectorFremanezumab-Vfrm13$8,852
Primidone120$3,161
Carbamazepine ErCarbamazepine16$2,847
Gabapentin192$2,638
Lacosamide25$2,496
Scopolamine13$2,396
Dimethyl Fumarate13$2,320
Levetiracetam75$2,027
Donepezil Hcl189$1,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,452$21,98113 claims
UCB, Inc.Briviact$649$16,56112 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$294$58411 claims
Upsher-smith Laboratories LLCTopiramate$89$51451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 381 neurology providers in Missouri.

Other neurology in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →